Illumina dient patentinbreukprocedures in tegen BGI in Zweden en het Verenigd Koninkrijk
SAN DIEGO– (BUSINESS WIRE) – Illumina, Inc. (NASDAQ: ILMN) heeft vandaag aangekondigd dat het twee extra rechtszaken wegens inbreuk op het patent heeft ingediend met betrekking tot BGI’s sequencingproducten, waaronder de DNBSeq-400 (ook bekend als MGISeq-2000), DNBSeq- T7 en gerelateerde chemiereagentia.
De eerste klacht werd ingediend tegen MGI Tech Co., Ltd. en Letland MGI Tech SIA bij het High Court of Justice, Chancery Division, Patents Court in het Verenigd Koninkrijk wegens schending van vier octrooien: EP 1 530 578 B1, EP 1 828 412 B2, EP 2 021 415 BI en EP 3 002 289 B1. De tweede klacht werd ingediend tegen MGI Tech SIA in Letland bij het Patent and Market Court in Zweden wegens schending van EP 3 002 289 B1. De patenten hebben betrekking op de eigen chemie van Illumina.
Gerelateerde patentprocedures zijn in behandeling in Denemarken, Duitsland, Zwitserland, Turkije en de Verenigde Staten.
Illumina Files Patent Infringement Suits Against BGI in Sweden and the United Kingdom
SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI’s sequencing products, including the DNBSeq-400 (also known as MGISeq-2000), DNBSeq-T7, and related chemistry reagents.
The first complaint was filed against MGI Tech Co., Ltd. and Latvia MGI Tech SIA in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom alleging infringement of four patents: EP 1 530 578 B1, EP 1 828 412 B2, EP 2 021 415 B1, and EP 3 002 289 B1. The second complaint was filed against Latvia MGI Tech SIA in the Patent and Market Court in Sweden alleging infringement of EP 3 002 289 B1. The patents cover Illumina’s proprietary sequencing-by-synthesis chemistry.
Related patent suits are pending in Denmark, Germany, Switzerland, Turkey and the United States.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200110005033/en/
Contacts
Illumina, Inc.
Investors:
Jacquie Ross, CFA
+1-858-255-5243
Media:
Eric Endicott
858-882-6822
Media – Europe, Middle East & Africa:
Karen Birmingham
+44(0) 7500105665